. 2021 Aug 3;28(10):5730–5741. doi: 10.1245/s10434-021-10459-3

Table 2.

Surgical and adjuvant treatment for hormone receptor-positive (HR+) cT2-4 breast cancer patients (NCDB 2010–2016)

Characteristics	n	Neoadjuvant chemotherapy (n=14025)	n	Neoadjuvant endocrine therapy (n=5804)	P value
Characteristics	n	%	n	%	P value
Breast surgery type					< 0.001
Partial mastectomy	4420	31.52	2779	47.88
Unilateral mastectomy	6833	48.72	2570	44.28
Bilateral mastectomy	2772	19.76	455	7.84
Axillary surgery type					< 0.001
SLNB (1–5 lymph nodes)	4771	34.02	2732	47.07
ALND (>5 lymph nodes)	8203	58.49	2253	38.82
No axillary surgery or unknown	1051	7.49	819	14.11
Adjuvant chemotherapy^a
Yes	NA	NA	1497	25.79
Unknown	0	0	125	2.15
Adjuvant endocrine therapy^b
Yes	12,150	86.63	NA	NA
Unknown	262	1.87	0	0
Radiation therapy					< 0.001
No	2771	19.76	2405	41.44
Yes	10,889	77.64	3222	55.51
Unknown	365	2.6	177	3.05

NCDB National Cancer Database, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection

^aThe sequence of treatment was used to determine whether neoadjuvant endocrine therapy (NET) patients received adjuvant chemotherapy.

^bThe sequence of treatment was used to determine whether neoadjuvant chemotherapy (NCT) patients received adjuvant endocrine therapy.